-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Scientists at the National Cardiovascular Research Center (CNIC) have discovered a new mechanism involved in the regulation of cardiac hypertrophy
The findings, published in the journal Circulation Research, may stimulate the development of new tools for the treatment of cardiac hypertrophy, especially in patients with Cushing’s syndrome
Dr.
The contractile function of the heart depends on the activity of cardiomyocytes
An example of this ability is the response to aortic stenosis
Although cardiomyocytes cannot divide, Dr.
However, although this response was effective at first, thickening of the left ventricular wall (thickness of the heart muscle) triggers structural changes in the heart, leading to a gradual loss of contractility
Dr.
Researchers found that mice lacking the rna-binding protein SRSF4 developed myocardial hypertrophy and impaired myocardial relaxation.
Further analysis showed that the deletion of SRSF4 severely reduced the expression of non-coding RNA GAS5
The first author, Dr.
The research team concluded that identifying the srsf4-gas5-glucocorticoid receptor cell signaling pathway is an important advancement in characterizing the molecular mechanism of cardiac hypertrophy and may lay the foundation for new treatments
In addition, the findings may be “especially applicable to patients with Cushing’s syndrome, whose heart hypertrophy is partly activated by glucocorticoid receptors
Analysis of samples from patients with Cushing’s syndrome showed that the expression of SRSF4 and GAS5 was dysregulated to a certain extent; however, the possible role of this pathway in the disease needs further study
.
DOI 10.
1016 / j.
jacc.
2021.
07.
003
The SRSF4–GAS5-Glucocorticoid Receptor Axis Regulates Ventricular Hypertrophy